AllopurinolBenefits, Dosage & Interactions
Also known as: Zyloprim
Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production, used to prevent gout flares, tophi, uric acid kidney stones and tumour lysis syndrome. It is typically taken with a meal. The reported plasma half-life is about 1 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
3 human randomized trials and regulatory approval on file.
Quick answer
Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production, used to prevent gout flares, tophi, uric acid kidney stones and tumour lysis syndrome. It is preventive, not a treatment for an attack in progress, and can trigger flares in the first months, so clinicians often add colchicine or an anti-inflammatory cover. Its most serious risk is a rare severe hypersensitivity reaction.
- Class
- Xanthine oxidase inhibitor (urate-lowering therapy)
- Brand names
- Zyloprim, Aloprim, Zyloric
- Main uses
- Gout prevention, uric acid stones, tumour lysis syndrome
- Onset
- Uric acid falls within days; flare protection builds over months
- Key monitoring
- Serum urate target, renal function, liver enzymes
- Serious risk
- Allopurinol hypersensitivity syndrome; higher with HLA-B*58:01
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The cited trials used start-low go-slow titration from 50-100 mg per day up to individualized maintenance doses of 300 mg per day or higher, adjusted to reach a target serum urate level[1][2][3]
Reported for Allopurinol in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Allopurinol entry is written from. Each number matches an inline marker above.
- [1]Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialMackenzie IS, Ford I, Nuki G, et al. · Lancet · 2020 · Peer-reviewed · PMID 33181081
- [2]Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled TrialDalbeth N, Doyle AJ, Billington K, et al. · Arthritis & Rheumatology · 2019 · Peer-reviewed · PMID 31081595
- [3]Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trialStamp LK, Chapman PT, Frampton C, et al. · Annals of the Rheumatic Diseases · 2023 · Peer-reviewed · PMID 37652661
How to track Allopurinol doses
Tracking Allopurinol well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Allopurinol with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is with_meal. Take it with food, and record it that way so absorption stays consistent. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Allopurinol through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 1 h, effects and timing shifts show up over days rather than instantly. Review Allopurinol alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day and whether it was taken with food
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Allopurinol dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Allopurinol?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
What does the research say about Allopurinol?
Tap a section to expand.
Source for this section: Sources for How does Allopurinol work?: Jumps to this entry in the sources and references list at the end of the page.
Source for this section: Sources for When should you take Allopurinol?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Allopurinol?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Allopurinol
Which studies looked at Allopurinol?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Febuxostat compared with allopurinol in patients with hyperuricemia and gout(opens PubMed in a new tab)N Engl J Med · 2005 · PMID 16339094 · https://pubmed.ncbi.nlm.nih.gov/16339094/
- 2.Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial(opens PubMed in a new tab)Lancet · 2020 · PMID 33181081 · https://pubmed.ncbi.nlm.nih.gov/33181081/
- 3.Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout(opens PubMed in a new tab)N Engl J Med · 2018 · PMID 29527974 · https://pubmed.ncbi.nlm.nih.gov/29527974/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 135401907(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/135401907
Verify at
Publisher search links for Allopurinol. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Allopurinol?
Plain-text summary, safe to quote verbatim:
Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production, used to prevent gout flares, tophi, uric acid kidney stones and tumour lysis syndrome. It is typically taken with a meal. The reported plasma half-life is about 1 hours, which shapes dosing frequency.
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Allopurinol — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/allopurinol
What compounds are similar to Allopurinol?
Others in the medication category or studied for the same goals.
